228 related articles for article (PubMed ID: 9011381)
21. [Antibiotic resistance to erythromycin, clindamycin and tetracycline of 573 strains of Streptococcus pyogenes (1992-1994)].
Orden B; Martínez R; López de los Mozos A; Franco A
Enferm Infecc Microbiol Clin; 1996 Feb; 14(2):86-9. PubMed ID: 8714154
[TBL] [Abstract][Full Text] [Related]
22. Group A streptococci. Erythromycin resistance and penicillin tolerance.
Savoia D; Millesimo M; Dotti G; Milano F
Adv Exp Med Biol; 1997; 418():447-9. PubMed ID: 9331690
[No Abstract] [Full Text] [Related]
23. Clinical and microbiological evaluation of miocamycin activity against group A beta-haemolytic streptococci in pediatric patients. Three years' incidence of erythromycin-resistant group A streptococci.
Borzani M; Varotto F; Garlaschi L; Conio F; Dell'Olio M; Careddu P
J Chemother; 1989 Jul; 1(4 Suppl):392-4. PubMed ID: 16312455
[No Abstract] [Full Text] [Related]
24. Decrease of erythromycin resistance in group A streptococci by change of emm distribution.
Koh EH; Kim S; Lee NY
Jpn J Infect Dis; 2008 Jul; 61(4):261-3. PubMed ID: 18653965
[TBL] [Abstract][Full Text] [Related]
25. Macrolide-resistant group a streptococcus--now in the United States.
Huovinen P
N Engl J Med; 2002 Apr; 346(16):1243-5. PubMed ID: 11961156
[No Abstract] [Full Text] [Related]
26. [Isolated susceptibility of Streptococcus pyogenes to 3 macrolides].
Sakran W; Raz R; Colodner R; Keness Y
Harefuah; 1997 Nov; 133(9):365-6, 414. PubMed ID: 9418339
[TBL] [Abstract][Full Text] [Related]
27. [Streptococcus pyogenes: penicillin and erythromycin susceptibility in the cities of Neuquen and Cipolletti].
Soriano SV; Brasili S; Saiz M; Carranza C; Vidal P; Calderón J; Lopardo HA
Medicina (B Aires); 2000; 60(4):487-90. PubMed ID: 11188957
[TBL] [Abstract][Full Text] [Related]
28. Identification of an erm(T) gene in strains of inducibly clindamycin-resistant group B Streptococcus.
Dipersio LP; Dipersio JR
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):189-93. PubMed ID: 16989973
[TBL] [Abstract][Full Text] [Related]
29. Dissemination of emm28 erythromycin-, clindamycin- and bacitracin-resistant Streptococcus pyogenes in Spain.
Perez-Trallero E; Garcia C; Orden B; Marimon JM; Montes M
Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):123-6. PubMed ID: 14712367
[TBL] [Abstract][Full Text] [Related]
30. [Investigation of erythromycin resistance and resistance phenotypes in group A beta hemolytic streptococci].
Kaya EG; Yücel M; Karakoç AE
Mikrobiyol Bul; 2006 Jul; 40(3):161-8. PubMed ID: 17001844
[TBL] [Abstract][Full Text] [Related]
31. Plasmid-Borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains.
Woodbury RL; Klammer KA; Xiong Y; Bailiff T; Glennen A; Bartkus JM; Lynfield R; Van Beneden C; Beall BW;
Antimicrob Agents Chemother; 2008 Mar; 52(3):1140-3. PubMed ID: 18180360
[TBL] [Abstract][Full Text] [Related]
32. Decreased erythromycin use after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan.
Hsueh PR; Shyr JM; Wu JJ
Clin Infect Dis; 2005 Mar; 40(6):903-5. PubMed ID: 15736030
[No Abstract] [Full Text] [Related]
33. [Susceptibility of Streptococcus pyogenes to penicillin, macrolides and clindamycin in Cádiz].
Marín P; Márquez A; García-Martos P; García-Tapia A; Tapia J
Rev Esp Quimioter; 2000 Sep; 13(3):318-9. PubMed ID: 11086284
[No Abstract] [Full Text] [Related]
34. [Streptococcus pyogenes an emerging pathogen].
Cohen R; Aujard Y; Bidet P; Bourrillon A; Bingen E; Foucaud P; François M; Garnier JM; Gendrel D; Guillot M; Hau I; Olivier C; Quinet B; Raymond J
Arch Pediatr; 2005 Jul; 12(7):1065-7. PubMed ID: 15913971
[No Abstract] [Full Text] [Related]
35. Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic streptococci in Korea.
Uh Y; Jang IH; Hwang GY; Lee MK; Yoon KJ; Kim HY
Antimicrob Agents Chemother; 2004 Jul; 48(7):2716-8. PubMed ID: 15215133
[TBL] [Abstract][Full Text] [Related]
36. Macrolide resistance in group A beta haemolytic Streptococcus isolated from outpatient children in Latvia.
Zavadska D; Bērziņa D; Drukaļska L; Pugacova N; Miklasevics E; Gardovska D
APMIS; 2010 May; 118(5):366-70. PubMed ID: 20477812
[TBL] [Abstract][Full Text] [Related]
37. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients.
Bingen E; Fitoussi F; Doit C; Cohen R; Tanna A; George R; Loukil C; Brahimi N; Le Thomas I; Deforche D
Antimicrob Agents Chemother; 2000 Jun; 44(6):1453-7. PubMed ID: 10817692
[TBL] [Abstract][Full Text] [Related]
38. [Disappearance of Streptococcus pyogenes macrolide resistance in an area of northeastern Italy: a possible link with rational long-acting macrolide consumption].
De Rosa R; Avolio M; Stano P; Modolo ML; Camporese A
Infez Med; 2009 Jun; 17(2):82-7. PubMed ID: 19602920
[TBL] [Abstract][Full Text] [Related]
39. T serotyping and genomic profile of erythromycin-resistant or -sensitive Streptococcus pyogenes isolated in Campania Region, Italy.
Catalanotti P; Catania MR; Lucido M; Martini S; Gallè F; Ortega De Luna L; Rossano F
J Chemother; 2005 Apr; 17(2):131-7. PubMed ID: 15920897
[TBL] [Abstract][Full Text] [Related]
40. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Miller AL; Rice CL; Doern CD; Reid SD; Doern GV
Clin Infect Dis; 2005 Sep; 41(5):599-608. PubMed ID: 16080080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
